Copyright
©The Author(s) 2016.
World J Gastroenterol. Nov 7, 2016; 22(41): 9172-9185
Published online Nov 7, 2016. doi: 10.3748/wjg.v22.i41.9172
Published online Nov 7, 2016. doi: 10.3748/wjg.v22.i41.9172
Table 1 Demographic, clinical and laboratory characteristics of patients with or without bacterial infections
Non-infected | Infected | P value | ||||
n | 141 | 75 | ||||
Gender (male/female) | 77/64 | 41/34 | NS | |||
Age (yr) | 57.3 ± 10.7 | 58.1 ± 9.7 | NS | |||
Child-Pugh score | 6.9 ± 1.7 | 9.3 ± 2.2 | < 0.001 | |||
Child-Pugh stage, n (%) | ||||||
A | 58 (41.1) | 6 (8.0) | < 0.001 | |||
B | 65 (46.1) | 28 (37.3) | ||||
C | 18 (12.8) | 41 (54.7) | ||||
MELD score | 12.3 ± 4.1 | 19.1 ± 9.1 | < 0.001 | |||
Serum bilirubin (μmol/L) | 41.4 ± 38.3 | 124.1 ± 147.4 | < 0.001 | |||
Serum albumin (g/L) | 35.4 ± 7.1 | 28.1 ± 6.5 | < 0.001 | |||
INR | 1.3 ± 0.2 | 1.6 ± 0.5 | < 0.001 | |||
Serum creatinine (μmol/L) | 83.8 ± 74.3 | 131.2 ± 129.9 | < 0.001 | |||
Ascites present, n (%) | 58 (41.1) | 59 (78.7) | < 0.001 | |||
HCC, n (%) | 4 (2.8) | 11 (14.7) | 0.003 | |||
Comorbidities present, n (%) | 72 (51.1) | 45 (60.0) | NS | |||
Type of bacterial infections, n (%) | ||||||
UTI | 25 (29.4) | |||||
SBP | 20 (23.5) | |||||
Pneumonia | 18 (21.2) | |||||
SSTI | 4 (4.7) | |||||
Miscellaneous | 18 (21.2) | |||||
Multiple | 9 (10.6) | |||||
Acute phase proteins, median (IQR) | ||||||
Presepsin (pg/mL) | Overall | 477 (332-680) | 1002 (575-2149) | < 0.001 | ||
OF absent | OF present | 710 (533-1277) | 2357 (1398-3666) | < 0.001 | ||
CRP (mg/L) | Overall | 4.6 (1.8-8.8) | 30.1 (11.3-57.4) | < 0.001 | ||
OF absent | OF present | 25 (9.6-40.5) | 52.2 (23.4-84) | 0.027 | ||
PCT (μmol/L) | Overall | 0.1 (0.1-0.2) | 0.4 (0.1-1.2) | < 0.001 | ||
OF absent | OF present | 0.2 (0.1-0.5) | 1.7 (0.6-5.3) | < 0.001 |
Table 2 Association of classic acute phase proteins with mortality in patients with cirrhosis
Ref. | Year | Journal | Population | n | Outcome | Measure | Value |
C-reactive protein | |||||||
Reuken et al[72] | 2013 | Liver Int | Ascites | 108 | 90-d mortality | AUC | 0.69 (0.59-0.79), P = 0.001 |
Moreno et al[69] | 2013 | Liver Int | Non-septic | 95 | 1-yr mortality | AUC | 0.71 (0.6-0.8), P < 0.001 |
Mortensen et al[70] | 2012 | Eur J Gastroenterol Hepatol | Stable alcohol cirrhosis | 45 | Long term mortality (about 6- yr) | HR1 | |
1.074 (1.001-1.153), P = 0.046 | |||||||
Wiese et al[74] | 2014 | Liver Int | Stable cirrhotic | 193 | 1- yr survival | HR | 1.18, P = 0.0483 |
Lim et al[68] | 2014 | Plos One | SBP | 75 | 30-d mortality | AUC | 0.64 (0.49-0.79), P = 0.076 |
HR | ND, P = 0.064 | ||||||
Schwabl et al[73] | 2015 | Liver Int | SBP | 168 | 30-d mortality | HR1 | 1.067 (1.004-1.134), P = 0.037 |
Ha et al[65] | 2011 | Korean J Intern Med | Bacteraemia | 202 | 30-d mortality | Difference | Survivor vs non-survivor2 |
37.8 vs 34.3 mg/L, P = 0.721 | |||||||
Cervoni et al[20] | 2012 | J Hepatol | CPs > 7 | 148 | 180-d mortality | AUC | 0.63 (0.51-0.73), P = ND |
HR14 | 2.73 (1.41-5.26), P = 0.003 | ||||||
Di Martino et al[64] | 2015 | Liver Transplant | CPs > 7 | 109 | 90-d mortality | HR14 | 2.21 (1.03-4.76), P = 0.042 |
Cervoni et al[63] | 2016 | Eur J Gastroenterol Hepatol | CPs > 7 | 583 | 90-d mortality | HR14 | 1.69 (1.01-2.81), P = 0.046 |
Park et al[71] | 2015 | J Korean Med Sci | Alcoholic cirrhosis various reasons for admission | 409 | 30-d mortality | OR | "CRP > 20 not independent predictor" |
Ximenes et al[75] | 2016 | Am J Emerg Med | Hepatic decompensation | 149 | Inhospital mortality | OR | OR: ND, P > 0.100 |
Kwon et al[67] | 2015 | BMC Gastroenterol | Acute decompensation | 184 | 30 d survival | OR | OR: ND, P = 0.122 |
Lazzarotto et al[19] | 2013 | Ann Hepatol | Acute decompensation | 64 | 90 d survival | Difference | Survivor vs non-survivor2 |
7 vs 41 mg/L, P = 0.026 | |||||||
Kronenberger et al[66] | 2012 | BMC Med | Acute decompensation + outpatients | 120 | Overall survival (196 ± 165 d) | HR | Univariate: 0.314 (0.141-0.702) , P = 0.005 |
Multivariate: ND, P = 0.077 | |||||||
Procalcitonin | |||||||
Lin et al[80] | 2015 | J Crit Care | Acute decompensation | 96 | Sepsis in-hospital mortality | AUC | 0.692 |
Kotecha et al[79] | 2013 | Eur J Gastroenterol Hepatol | Cirrhosis + SIRS | 100 | In-hospital survival | OR1 | 0.949 (0.868-1.037), P = 0.249 |
Connert et al[78] | 2003 | Z Gastroenterol | Compensated + decompensated | 100 | 60-d mortality | Percent died | < 0.58 vs≥ 0.58: |
9.1% vs 46.7%, P < 0.001 | |||||||
Al-Dorzi et al[76] | 2014 | Clin Lab | Septic shock | 45 | 28-d mortality | Difference | Low PCT vs high PCT: |
80% vs 77%, P = 0.61 | |||||||
Berres et al[77] | 2009 | Liver Int | Critically ill | 38 | ICU mortality | Difference | NA, P = NS |
Table 3 Correlations between presepsin and different laboratory parameters or liver-orientated scores
Variable | Spearman’s rho | P value |
CRP | 0.63 | < 0.001 |
PCT | 0.53 | < 0.001 |
Leucocyte count | 0.27 | < 0.001 |
Serum creatinine | 0.36 | < 0.001 |
Serum bilirubin | 0.28 | < 0.001 |
Serum albumin | -0.40 | < 0.001 |
INR | 0.15 | 0.032 |
CPs | 0.42 | < 0.001 |
MELD score | 0.45 | < 0.001 |
Table 4 Performance characteristics of presepsin and other acute phase proteins during bacterial infections in patients with cirrhosis in various clinical settings
Variable | Cut-off values | Sensitivity | Specificity | PPV | NPV | LR+ | LR- | |
INF overall | Presepsin (pg/mL) | 844 | 60.0% | 84.45 | 67.2% | 79.9% | 3.85 | 0.47 |
PCT (μmol/L) | 0.39 | 53.3% | 93.65 | 81.6% | 79.0% | 8.36 | 0.50 | |
CRP (mg/L) | 10.8 | 78.7% | 84.4% | 78.2% | 88.1% | 5.04 | 0.25 | |
At least one marker positive (Presepsin/CRP) | 88.0% | 74.5% | 64.7% | 92.1% | 3.45 | 0.16 | ||
At least one marker positive (PCT/CRP) | 81.3% | 84.2% | 69.3% | 91.1% | 5.15 | 0.22 | ||
INF + OF | Presepsin (pg/mL) | 1206 | 87.5% | 74.5% | 61.8% | 92.75 | 3.43 | 0.17 |
PCT (μmol/L) | 0.5 | 79.2% | 76.5% | 61.3% | 88.6% | 3.36 | 0.27 | |
CRP (mg/L) | 40.5 | 62.5% | 76.5% | 55.6% | 81.2% | 2.66 | 0.49 |
Table 5 Performance characteristics of presepsin, procalcitonin and C-reactive protein for prediction of short-term (28-d) mortality in patients with bacterial infection (n = 75)
Variable | Cut-off values | AUC-ROC (95%CI) | Sensitivity | Specificity | PPV | NPV | LR+ | LR- |
Presepsin (pg/mL) | 1277 | 0.76 (0.64-0.85) | 75.0% | 69.1% | 46.9% | 88.4% | 2.43 | 0.36 |
PCT (μmol/L) | 0.48 | 0.87 (0.77-0.93) | 90.0% | 74.6% | 56.2% | 95.3% | 3.54 | 0.13 |
CRP (mg/L) | 39.6 | 0.74 (0.63-0.84) | 75.0% | 74.6% | 51.7% | 89.1% | 2.95 | 0.34 |
Table 6 Association of presepsin, procalcitonin and C-reactive protein levels with short-term (28-d) mortality in patients with cirrhosis and bacterial infection
Binary logistic regression analysis | ||||||||
Univariate | Multivariate | |||||||
Unadjusted | P value | Adjusted for MELD | P value | Adjusted for leucocyte count | P value | Adjusted for MELD and leucocyte count | P value | |
ln(Presepsin) | 3.59 (1.65-7.84) | 0.001 | 1.9 (0.81-4.43) | 0.138 | 2.91 (1.28-6.64) | 0.011 | 1.61 (0.65-3.97) | 0.303 |
ln(PCT) | 2.54 (1.55-4.16) | < 0.001 | 1.89 (1.14-3.14) | 0.014 | 2.33 (1.42-3.83) | 0.001 | 1.81 (1.09-3.01) | 0.022 |
ln(CRP) | 2.17 (1.23-3.81) | 0.007 | 1.73 (0.93-3.21) | 0.081 | 1.84 (1.03-3.31) | 0.040 | 1.56 (0.81-2.99) | 0.180 |
- Citation: Papp M, Tornai T, Vitalis Z, Tornai I, Tornai D, Dinya T, Sumegi A, Antal-Szalmas P. Presepsin teardown - pitfalls of biomarkers in the diagnosis and prognosis of bacterial infection in cirrhosis. World J Gastroenterol 2016; 22(41): 9172-9185
- URL: https://www.wjgnet.com/1007-9327/full/v22/i41/9172.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i41.9172